Podcasts about baxter international inc

In this episode of Practical Pivots, host Steve Pockross sits down with Harry Kraemer, Kellogg Professor at Northwestern University and former Baxter International CEO, to explore the critical importance of values-based leadership; especially in turbulent times like these. Kraemer shares his transformative approach to leadership, emphasizing four key principles: self-reflection, balanced perspective, true self-confidence, and genuine humility. Through personal anecdotes and practical insights, he guides listeners on how to navigate complex business environments by staying true to core values, making difficult decisions with integrity, and understanding that leadership is less about technical skills and more about emotional intelligence, team building, and personal growth. This episode offers a compelling roadmap for leaders at any stage who want to lead with purpose and authenticity in today's challenging marketplace.About Harry Kraemer Harry Kraemer is a Professor of Leadership at Northwestern University's Kellogg School of Management. He's been named Professor of the Year multiple times, is the author of four best-selling leadership books, and is one of the most sought-after leaders in his field. He is the former Chairman and Chief Executive Officer of Baxter International Inc., a $12 billion global healthcare company.From Values to Action: The Four Principles of Values-Based Leadershiphttps://harrykraemer.org

> Sign Up For Our Newsletter: http://www.firsthuman.com/being-human-newsletter/   My guest this week is Harry M. Jansen Kraemer, Jr, Professor of Leadership at Northwestern University's Kellogg School of Management, author of multiple books on leadership and former CEO of Baxter International Inc., a $12 billion global healthcare company. Harry's professional trajectory was marked by rapid ascension and notable achievements in corporate leadership. Rising to the position of CEO earlier than anticipated, Kraemer distinguished himself through a leadership philosophy centered on influence rather than mere authority. His approach emphasizes self-awareness, genuine humility, and the ability to foster productive relationships across all organisational levels. His academic curriculum stresses the importance of self-reflection, work-life balance, and authentic leadership. His career exemplifies a blend of corporate acumen and social responsibility, positioning him as a respected figure in both business and academic circles. Included in the episode: A most unusual initiation to his future wife's family Self-reflection as rocket fuel for professional progression Befriending everyone you meet Harry's daily self-reflection ritual How to encourage even the most resistant to self reflect Links: Harry's Books One Acre Fund Daily and Annual Self-Reflection Questions

We would love to get your feedback on what you thought of this month's "Enloe's Message".Enloe Health has felt the impact of the nationwide IV shortage caused by damage to the Baxter International Inc. facility from Hurricane Helene in North Carolina.Learn how the health system has been affected in the November episode of Enloe's Message. Host Jolene Francis, Enloe Health's Vice President of Philanthropy & Communications, welcomes two guests to discuss the topic.Sean Maiorano, D.O., Enloe's Chief Medical Officer, and Chris Marking, Enloe's Senior Director of Pharmacy, shed light on the situation, what occurred and how Enloe Health is responding.

            For medical writing assistance, please visit nascentmc.com learnAMAstyle.com for the AI in Medical Writing and Editing: Blueprint for Success in a Changing World course to assist with implementing AI in medical writing.  •    Imdelltra for EC-SCLC: The FDA granted accelerated approval for tarlatamab-dlle (Imdelltra) for adults with extensive-stage small cell lung cancer (ES-SCLC) who progressed after platinum-based chemotherapy. Small cell lung cancer, accounting for 10-15% of all lung cancers, is aggressive with a median survival of 12 months post-therapy. Imdelltra, a first-in-class BiTE therapy targeting DLL3, showed a 40% objective response rate and a median overall survival of 14.3 months in the phase 2 DeLLphi-301 trial. •    Breyanzi for R/R LL: The FDA granted accelerated approval for lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory follicular lymphoma after two or more systemic therapies. This CAR T-cell therapy, already approved for other B-cell malignancies, genetically modifies T cells to target tumor antigens. In the TRANSCEND FL trial, Breyanzi achieved a 95.7% overall response rate in 94 patients, with the median response duration not reached after 16.8 months. •    SNB-101 for SCLC: The FDA granted fast-track designation to SNB-101 for small cell lung cancer (SCLC). SNB-101, a polymer nanoparticle formulation of the antineoplastic agent SN-38, enhances lung-specific delivery and efficacy. Early data indicates improved tolerability and efficacy, with global phase 2 trials planned for various solid tumors including colon and gastric cancers, led by SN BioScience. •    Upstaza for AADC Deficiency: The FDA accepted the Biologics License Application for eladocagene exuparvovec (Upstaza), a gene therapy for aromatic L–amino acid decarboxylase (AADC) deficiency, with a Priority Review and a target date of November 13, 2024. Upstaza delivers the human DDC gene to the putamen, increasing AADC enzyme levels to restore dopamine production, showing significant neurological improvements in clinical trials. Approval was granted to PTC Therapeutics, Inc. •    Altuviiio for Hemophilia A Label Update: The FDA approved an updated label for Altuviiio (antihemophilic factor, recombinant), including phase 3 XTEND-Kids trial results. This high-sustained factor VIII replacement therapy, initially approved in 2023, offers prolonged bleed protection for pediatric patients under 12 years with hemophilia A. The updated label confirms Altuviiio's safety and effectiveness for both routine and on-demand treatment. •    Self-Collected Sample for Cervical Cancer Screening: The FDA approved the BD Onclarity™ HPV Assay for self-collected vaginal specimens for HPV testing when traditional cervical samples are not available. This assay, identifying six HPV strains, enhances screening access, especially for underserved populations with higher cervical cancer rates. Approval was granted to Becton Dickinson. •    Clinolipid Parenteral Nutrition: The FDA approved Clinolipid (Lipid Injectable Emulsion) for pediatric patients, including preterm and term neonates. Clinolipid, a mixed oil lipid emulsion providing essential fatty acids and calories, has been available for adults since 2019 and is now approved for all ages. Approval was granted to Baxter International Inc.

How will AI shape or change the HR department? Should Human Resources be using AI? Thiébaud Groner, Senior Manager HR - M&A  at Baxter International Inc., joins us to discuss the future of HR and how the role of HR will change from business operations to management. Newsletter: Sign up for our free daily newsletterMore on this Episode: Episode PageJoin the discussion: Ask Thiébaud and Jordan questions about AI and HRUpcoming Episodes: Check out the upcoming Everyday AI Livestream lineupWebsite: YourEverydayAI.comEmail The Show: info@youreverydayai.comConnect with Jordan on LinkedInTimestamps:[00:01:30] Daily AI news[00:04:00] About Thiébaud Groner and Braxton International[00:06:09] AI's impact on HR[00:08:30] Use cases for AI in HR[00:15:45] Ways AI can personalize employee experiences[00:18:30] Using AI to flag issues[00:21:40] Will HR applications get an AI update?[00:24:30] More business use cases for AI in HR[00:27:00] Thiébaud Groner's advice on AI in HRTopics Covered in This Episode:1. Exploring the Role of HR and AI2. AI for HR Analytics and Documents3. HR as Change Agents for AI Adoption4. Implementing AI in HRKeywords:AI, human resources department, AI adoption, change the role of HR, understand AI, guest(s), terrorists, AI in terrorist activities, infrastructure security vulnerabilities, IBM, brain-inspired computer chip, North Pole, processing and memory integration, human brain, NVIDIA, GPU chip race, HR departments, reading and writing documents, HR work, job responsibilities, AI in HR practices, employee surveys, generative AI, increased productivity, Microsoft Copilot, ChatGPT, practical business use cases for AI, prompt engineering, productivity, leveraging existing employees, Workday, PowerPoint presentations, changing behavior, change agents for AI, success stories, AI literacy, international aspect of HR departments, HR documentation, nuances in language, rich analytics, off-the-shelf analytics, predictive analytics, European laws, document work assistance, privacy concerns, generative AI in document drafting, Jon Stewart, The Problem with Jon Stewart, Apple streaming platform, AI in China. Get more out of ChatGPT by learning our PPP method in this live, interactive and free training! Sign up now: https://youreverydayai.com/ppp-registration/

Linda speaks with Brad Thomas, an experienced leader, about the importance of culture and communication, leading by example, sharing the vision and the need for advancements in disruptive medical technology for the success of healthcare organizations. Brad was born and raised in South Wales, UK, and attained a BSc from Oxford Brookes University. He has worked in the UK and Canadian healthcare industries throughout his career in several sales & marketing roles for start-ups to large global corporations. He is currently an Associate Director, Commercial Excellence, Sales Operations & Enablement for Baxter International Inc.

On this episode, I was joined by Niedre Heckman, MPH, PhD, FRAPS, Director of Regulatory Affairs Strategy, CMC, Medical Devices, Combination Products at Takeda.  Niedre discusses: * Common Technical Document * Combination Products Structure for eCTD Submissions * EU vs. US Submission Expectations * Design Controls and Human Factors data placement * Regulatory Roles and Responsibilities in Pharma Niedre Heckman, PhD, MPH, FRAPS is the Director of Regulatory Affairs Strategy, CMC, Medical Devices, Combination Products at Takeda. She's a fellow of Regulatory Affairs Professionals Society (RAPS) (FRAPS), and holds an MPH and PhD in Public Health. Niedre has worked at Takeda, Baxter International Inc., Shire, Baxalta, 3M, and GSK. Niedre has a wide career in Regulatory Affairs, Quality, and Research with focuses in many modalities of medical devices, pharmaceuticals and combination products. Niedre couples her background in RA & QA with her expertise in public health to bring a uniquely patient centric point of view.

On this episode, I was joined by Niedre Heckman, MPH, PhD, FRAPS, Director of Regulatory Affairs Strategy, CMC, Medical Devices, Combination Products at Takeda. Niedre discusses: - Challenges with global regulatory strategies for combination products - Impact of regulatory strategies on patients and product adoption - Becoming an FRAPS, and building wide expertise in QA & RA - Being a great teammate/colleague Niedre Heckman, PhD, MPH, FRAPS is the Director of Regulatory Affairs Strategy, CMC, Medical Devices, Combination Products at Takeda. She's a fellow of Regulatory Affairs Professionals Society (RAPS) (FRAPS), and holds an MPH and PhD in Public Health. Niedre has worked at Takeda, Baxter International Inc., Shire, Baxalta, 3M, and GSK. Niedre has a wide career in Regulatory Affairs, Quality, and Research with focuses in many modalities of medical devices, pharmaceuticals and combination products. Niedre couples her background in RA & QA with her expertise in public health to bring a uniquely patient centric point of view.

The Winning ESG Companies articles include: “11 Best ESG Dividend Stocks to Buy According to Al Gore”; “Top 12 ESG Companies in 2022”; “IBD's 100 Best ESG Companies For 2022”; “Investing in green energy here are the top 5 stock picks”; “Capital Keeps Flowing Into Green Bonds Despite Inflation Challenges”; and much more this episode… Podcast: The Winning ESG Companies Transcript & Links, Episode 93, November 4, 2022 Hello, Ron Robins here. Welcome to my podcast episode 93 published on November 4, 2022, titled “The Winning ESG Companies” — and presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page located at investingforthesoul.com/podcasts. Now if any terms are unfamiliar to you, simply Google them. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, nor do I receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief so that I can get as many companies covered as possible in the time allowed. Please go to this podcast's webpage for links to the actual articles where you'll find much more great company information. ------------------------------------------------------------- 1) The Winning ESG Companies Now the content of this first article will likely interest most of you. It's titled 11 Best ESG Dividend Stocks to Buy According to Al Gore and found on yahoo.com. It's by Vardah Gill. Al Gore is a former U.S. Vice President, Nobel Peace Prize winner, and well-known for his environmental advocacy and investment management skills. He co-founded Generation Investment Management. Here's some of what Mr. Gill has to say. Incidentally, quoted dividend yields are as of October 28. “For this list, we selected stocks from Generation Investment Management's 13 F portfolio as of Q2 2022… Moreover, these companies pay dividends to shareholders. The stocks are ranked according to their stake values in the hedge fund's portfolio. 11. Microchip Technology Incorporated (NASDAQ:MCHP) Generation Investment Management's (G-I-M's) Stake Value: $76,630,000 Microchip Technology Incorporated is an Arizona-based manufacturing company that specializes in microcontrollers, mixed-signal, and other related circuits… It currently pays a quarterly dividend of $0.301 per share and has a dividend yield of 1.94%. 10. The Cooper Companies, Inc. (NYSE:COO) GIM's Stake Value: $394,222,000 The Cooper Companies currently pays a quarterly dividend of $0.015 per share, with a dividend yield of 0.02%. 9. Carlisle Companies Incorporated (NYSE:CSL) GIM's Stake Value: $408,039,000 Carlisle Companies Incorporated is an Arizona-based manufacturing company that specializes in a wide range of products including optical fibers and defense electronics… it pays a quarterly dividend of $0.75 per share and has a dividend yield of 1.24%. 8. Thermo Fisher Scientific Inc. (NYSE:TMO) GIM's Stake Value: $486,718,000 Thermo Fisher Scientific is an American supplier of scientific instruments, reagents, and other software products… It currently pays a quarterly dividend of $0.30 per share with a dividend yield of 0.24%. 7. Intel Corporation (NASDAQ:INTC) GIM's Stake Value: $552,560,000 Intel Corporation is an American multinational semiconductor company that also specializes in cloud computing and data centers…. It currently pays a quarterly dividend of $0.365 per share and has a dividend yield of 5.19%. 6. Applied Materials, Inc. (NASDAQ:AMAT) GIM's Stake Value: $555,224,000 Applied Materials is a California-based manufacturing company that supplies services and software for the manufacturing of semiconductor chips… The stock has a dividend yield of 1.19%. 5. Analog Devices, Inc. (NASDAQ:ADI) GIM's Stake Value: $649,049,000 Analog Devices is an American semiconductor manufacturing company that specializes in data conversion, signal processing, and power management technology… (It has) a quarterly dividend of $0.76 per share and… a dividend yield of 2.13%. 4. Becton, Dickinson and Company (NYSE:BDX) GIM's Stake Value: $789,414,000 Becton, Dickinson and Company is a New Jersey-based multinational medical device company… It pays a quarterly dividend of $0.87 per share, with a dividend yield of 1.49%. 3. The Charles Schwab Corporation (NYSE:SCHW) GIM's Stake Value: $800,177,000 The Charles Schwab Corporation is a Texas-based financial services company that offers investment and commercial banking services to its consumers… The stock has a dividend yield of 1.11%. 2. Baxter International Inc. (NYSE:BAX) GIM's Stake Value: $836,163,000 Baxter International is an American multinational healthcare company that specializes in kidney diseases and other chronic conditions… It currently pays a quarterly dividend of $0.29 per share and has a dividend yield of 2.09%. 1. Equifax Inc. (NYSE:EFX) GIM's Stake Value: $850,637,000 Equifax, a Georgia-based credit bureau company… Last year… announced that it will achieve net-zero greenhouse gas emissions by 2040… It currently pays a quarterly dividend of $0.39 per share and has a dividend yield of 0.94%.” End quotes. ------------------------------------------------------------- 2) The Winning ESG Companies This next article is also fascinating. You'll see in a moment. It's titled Top 12 ESG Companies in 2022 on yahoo.com. By Fahad Saleem. Here are some quotes from Mr. Saleem… “For this article we used the latest datasets of Just Capital a not-for-profit founded in 2013 by popular individuals like billionaire Paul Tudor Jones, Deepak Chopra, Rinaldo Brutoco, Arianna Huffington, Paul Scialla, Alan Fleischmann, among others. Just Capital ranks the largest US companies based on their performance related to issues concerning environment, workers, customers, communities and shareholders… We focused more on the environmental aspect of the ESG matrix of these companies… 12. Exelon Corporation (NASDAQ:EXC) Exelon Corporation is an Illinois-based utilities services company that owns nuclear, fossil, wind, hydroelectric, biomass, and solar generating facilities… claims to be the largest producer of zero-carbon electricity in the U.S. 11. PepsiCo, Inc. (NYSE:PEP) … in January last year announced that it plans to achieve net-zero greenhouse gas emissions across its supply chain by 2040. 10. Cisco Systems Inc. (NASDAQ:CSCO) In September last year, Cisco Systems Inc announced plans to reach net-zero emissions across all scopes by 2040. 9. Verizon Communications Inc. (NYSE:VZ) In 2019, it became the first US telecom company to issue a green bond. The offering raised about $1 billion in net proceeds. Verizon Communications has announced plans to generate renewable energy equivalent to 50% of its annual electricity consumption by 2025.  8. NVIDIA Corporation (NASDAQ:NVDA) The company says it's building a digital version of our planet on which it'll apply its AI and Omniverse technologies to predict weather changes and their effects over a span of several decades. NVIDIA Corporation GPUs will also be used to power the Department of Energy's supercomputer called ‘Kestrel' which is dedicated to advanced energy solutions. 7. Apple Inc. (NASDAQ:AAPL) … has an ambitious goal to become carbon neutral by 2030. 6. PayPal Holdings Inc. (NASDAQ:PYPL) Payments giant PayPal Holdings Inc announced last year that it plans to reach net-zero emissions by 2040. 5. Bank of America Corporation (NYSE:BAC) … has set a goal of achieving net zero greenhouse gas emissions by 2050. 4. Salesforce Inc. (NYSE:CRM) … announced in September 2021 that it achieved net-zero residual emissions across its full value chain and met its 100% renewable energy goal for its operations. 3. Microsoft Corporation (NASDAQ:MSFT) … plans to become carbon neutral by 2030… By 2050, Microsoft plans to remove the ‘historical emissions' it created since its founding. 2. Intel Corporation (NASDAQ:INTC) Earlier this year, Intel Corporation announced plans to achieve net-zero greenhouse gas emissions across its global operations by 2040. 1. Alphabet Inc. Class A (NASDAQ:GOOGL) … is the top ESG company in 2022, thanks to the billions of dollars' worth of ESG-related investments and ambitious goals it has set for the betterment of the environment. In its 2022 ESG report, the parent of Google said that it issued a whopping $5.75 billion in sustainability bonds, easily surpassing all peers in the industry.” End quotes. ------------------------------------------------------------- 3) The Winning ESG Companies Now to the first of our two company ranking lists. The reviewing article is titled IBD's 100 Best ESG Companies For 2022. It appears on investors.com and is by Kathleen Doler. Now some quotes from Ms. Doler. “Topping the list this year is Worthington Industries (WOR). J.B. Hunt Transport Services (JBHT) took second place. And rounding out the top three is data analytics provider Verisk Analytics (VRSK). All 100 companies on our 2022 list ranked in the top 15% of Dow Jones ESG scores and had an IBD Composite Rating of 81 or better (on a scale of 1 to 99), as of Aug. 31… Technology behemoths Texas Instruments (TXN) and Apple (AAPL) finished fourth and fifth respectively.” End quotes. ------------------------------------------------------------- 4) The Winning ESG Companies The second company ranking also has an intriguing background. It's called The Humankind 100 and this list is found on their site humankind.co. Here are some quotes from their site. “The Humankind 100 list is compiled annually by the research team at Humankind Investments, an investment manager whose mission is to invest in the manner that is best for humanity. You can learn more about the Humankind Value methodology by visiting our research or articles pages… Humankind 100 companies tend to contribute positively to humanity, for example by providing access to food, clean water, healthcare, or free digital services.” End quotes. Incidentally, though Humankind purports a unique methodology, they arrive at pretty much the same companies as most other 'best company ESG' lists. Nonetheless, they have an interesting concept that will appeal to many ethical and sustainable investors. Their top five companies are Alphabet, Inc. (GOOGL), Johnson & Johnson (JNJ), Pfizer Inc. (PFE), AbbVie Inc. (ABBV), and Verizon Communications Inc. (VZ). ------------------------------------------------------------- 5) The Winning ESG Companies Now back to a favorite sector with this article. It's titled Investing in green energy here are the top 5 stock picks on londonlovesbusiness.com. It's by LLB Finance Reporter. Here are some brief quotes with their picks. “With the green energy industry continually expanding, Maxim Manturov, Head of Investment Advice at Freedom Finance Europe, explores which companies are promising investment choices within the sector… (He chooses) Tesla (TSLA) Plug Power (PLUG) Enphase Energy (ENPH) Sunrun (RUN) First Solar (FSLR).” End quotes. ------------------------------------------------------------- Capital Keeps Flowing Into Green Bonds Despite Inflation Challenges Finally, we have this article titled Capital Keeps Flowing Into Green Bonds Despite Inflation Challenges by Ben Hernandez on etftrends.com. Here's some of what Mr. Hernandez says. “One option for fixed income investors looking for ESG bond exposure who also want the yield that corporate bonds can offer is the Vanguard ESG U.S. Corporate Bond ETF (VCEB). Additionally, the fund doesn't command a high premium with its low expense ratio of 0.12% and a 30-day SEC yield of 5.51%, as of October 17. (This bond fund) seeks to track the performance of the Bloomberg MSCI US Corporate SRI Select Index, which excludes bonds with maturities of one year or less and with less than $750 million outstanding, and it is screened for certain ESG criteria by the index provider, which is independent of Vanguard… The fund has a discerning screener. This adds an air of purity for VCEB's holdings, avoiding any greenwashing with a keen focus on environmental, social, and governance (ESG) initiatives. (It's) highlights: Provides debt issues screened for certain ESG criteria. Specifically excludes bonds of companies that the index sponsor determines are involved in and/or derive threshold amounts of revenue from certain activities or business segments related to adult entertainment, alcohol, gambling, tobacco, nuclear weapons, controversial weapons, conventional weapons, civilian firearms, nuclear power, genetically modified organisms, or thermal coal, oil, or gas. Excludes bonds of companies that, as determined by the index sponsor, do not meet certain standards defined by the index sponsor's ESG controversies assessment framework, as well as firms that fail to have at least one woman on their boards.” End quotes. ------------------------------------------------------------- One Other Honorable Mention Title: Top 5 Renewable Energy Stocks For Q4 2022 on forbes.com. By Q.ai. Canadian article Title: 10 Best ESG ETFs in Canada for Ethical Investing in (2022) - on savvynewcanadians.com. By Enoch Omololu. India article Title: Best ESG Funds in India: How Are They Different from Other Mutual Funds? On indmoney.com. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips -- for this podcast: “The Winning ESG Companies.” Now, please be sure to click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope in these deeply troubled times! Contact me if you have any questions. Thank you for listening. Talk to you next on November 18th. Bye for now. © 2022 Ron Robins, Investing for the Soul

The values you uphold are one of the most crucial aspects of leadership. Knowing and promoting those values as a leader helps you influence and govern your team in the right direction. And by adhering to your values, you inspire others to follow and adopt them.   In this episode of Fifth Dimensional Leadership, I interview Harry Kraemer, Jr. Harry is an executive partner at Madison Dearborn Partners, a private equity firm based in Chicago. He is also a Clinical Professor of Leadership at Northwestern University's Kellogg School of Management.  In our conversation, Harry talks about leading and positively influencing people through values-based leadership.   Harry is the author of three best-selling leadership books: From Values to Action: The Four Principles of Values-Based Leadership; Becoming The Best: Build a World-Class Organization Through Values-Based Leadership. and Your 168: Finding Purpose and Satisfaction in a Values-Based Life.   Harry is the former chairman and CEO of Baxter International Inc., a $13 billion global healthcare company. He joined Baxter in 1982 as director of corporate development and was named senior vice president and chief financial officer in 1993. In the following years, he assumed additional responsibility in Baxter's Renal and Medication Delivery businesses, was elected to Baxter's board of directors in 1995, and was named president of Baxter International Inc. in 1997.    Harry graduated summa cum laude from Lawrence University of Wisconsin with a bachelor's degree in mathematics and economics. He received an MBA degree in finance and accounting from Northwestern University's Kellogg School of Management and is a certified public accountant.  Things you will also learn in this episode: Putting things in perspective through math. Three things Harry did as CEO at Baxter that drove success. Distinguishing between values and preferences What it means to be liked vs. being respected. Examples of effective communication and setting boundaries. Quotes: “It's when you get to explain things that you realize you understand it.” - Harry Kraemer   “Values are non-negotiable, must not be compromised, and should be laid out very clearly.” - Harry Kraemer   “As a leader, when you're leading, the goal is not to be right; the goal is to do the right thing.” - Harry Kraemer   “This whole idea of leadership has nothing to do with titles and organizational charts, but it has everything to do with the ability to influence people.” - Harry Kraemer   “The more you know about any topic, the more you know how little you know. - Harry Kraemer   “You can learn something from every single person you encounter, and when that light goes on and you realize how much you can learn by every encounter, it changes your life.” - Harry Kraemer   “Develop a balanced perspective… seek to understand before you are understood.” - Harry Kraemer

Tyson takes in a weird beast, and the duo discusses strange human happenings with Elena Suaste, conflict resolution and workplace investigations specialist at Baxter International Inc. We discuss how to dig through the layers of employee complaints and claims, how to make employees feel heard, and how to identify when someone is trying to get fired. On purpose. You never knew ethics and compliance could be this… strange. Join us for the investigation, and don't miss this one! * Want to connect with Elena? You can reach out on LinkedIn, Or Check out her blog! *   Tyson and Alexa will be recording LIVE at PERKSCon San Francisco on September 15th, 2022, and in Los Angeles on September 21st, 2022.  Go to perkscon.com and click GET TICKETS to meet us live at the events - use the code PEOPLEPROBS at checkout for 30% off tickets.    *   FOLLOW US!   Watch this episode on YouTube!   Follow the podcast on Linkedin, Instagram, and TikTok at @peopleproblemspod   Follow the hosts on Instagram and LinkedIn:  Alexa Baggio (@alexabagadonuts) & LinkedIn Tyson Mackensie (@hr.shook)

Our latest episode of the Leader's Agenda features Kenneth Burhop, a lifetime innovator within Life Sciences. Ken recently retired from his position as the Chief Scientific Officer at Integra LifeSciences! Before Integra, Ken worked at Baxter International Inc. as their Global Scientific Lead and VP of R&D cumulatively for 25 years! Tarja Huuskonen had a chance to sit down with Ken and ask him how he has built innovation agendas in companies both large and small and what advice he has for others trying to develop not just one breakthrough but a pipeline of innovation.

In this episode, Marla Persky, CEO and President of WOMN LLC, talks about her experience serving on Corporate Boards of Directors. If you are thinking about serving on a board, Marla shares questions you should consider and reflect on before deciding to pursue board service. She provides tips on how to best position yourself to be considered for a corporate Board position. Talks about the types of experiences and expertise one should develop, including the” ins and outs'' of board service. WOMN LLC is a company dedicated to helping women succeed in the business of law by increasing their knowledge of and acuity with financial drivers, client development, and leadership. Throughout her professional life, Ms. Persky has had the opportunity to understand and practice business principles that lead to personal and company success. About Marla Persky Ms. Persky retired in 2013 as Senior Vice President, General Counsel and Corporate Secretary for Boehringer Ingelheim Inc., where she oversaw a department of over 70 individuals. She also was a member of Boehringer's executive management team and a director of the company and several of its subsidiaries. Prior to joining Boehringer Ingelheim, Ms. Persky spent 19 years at Baxter International Inc. where she held numerous business and legal positions, the most recent of which was Acting General Counsel and Corporate Secretary. During her career at Baxter, Ms. Persky managed global legal services, was General Manager of an international medical device business, led international crisis management teams, acquired and integrated international businesses, and designed/implemented strategies to manage global mass torts. Ms. Persky currently serves on the Audit and Chairs the Governance Committees of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company that leverages proprietary non-aqueous formulation technology platforms. She is also on the Audit and Strategic Planning Committees of the Board of Directors of YGEIA, a medical informatics technology company, and is on the Board of Advisors of Text IQ, a technology company that harnesses the power of artificial intelligence to prevent legal, compliance and reputational disasters. Previously, she served on the Board of Directors of Cytyc Corporation (NASDAQ: CYTYC) a device and diagnostics company. She was also on the Board of Boehringer Ingelheim Corporation, the world's largest privately owned pharmaceutical company. Ms. Persky was a director of Watermark, Inc. a private publisher and broker of children's literature. Connect with Marla on LinkedIn: Marla Persky | LinkedIn To connect to Simone and Your Choice Coach: www.YourChoiceCoach.com www.linkedin.com/in/simonesloan https://yourchoicecoach.com Twitter: @AimInspireGrow Facebook: https://www.facebook.com/YourBusinessGreatness YouTube: Your Business Greatness

Marla Persky is CEO and President of WOMN LLC, a company dedicated to helping women succeed in the business of law by increasing their knowledge of and acuity with financial drivers, client development, and leadership. Throughout her professional life, Ms. Persky has had the opportunity to understand and practice business principles that lead to personal and company success. Ms. Persky retired in 2013 as Senior Vice President, General Counsel and Corporate Secretary for Boehringer Ingelheim Inc., where she oversaw a department of over 70 individuals. She also was a member of Boehringer's executive management team and a director of the company and several of its subsidiaries. Prior to joining Boehringer Ingelheim, Ms. Persky spent 19 years at Baxter International Inc. where she held numerous business and legal positions, the most recent of which was Acting General Counsel and Corporate Secretary. During her career at Baxter, Ms. Persky managed global legal services, was General Manager of an international medical device business, led international crisis management teams, acquired, and integrated international businesses, and designed/implemented strategies to manage global mass torts. Ms. Persky currently serves on the Audit and Chairs the Governance Committees of Xeris Pharmaceuticals, Inc.(NASDAQ: XERS), a specialty pharmaceutical company that leverages proprietary non-aqueous formulation technology platforms. She is also on the Board of Directors of Revolo Biotherapeutics and serves on the Audit and Strategic Planning Committees of the Board of Directors of YGEIA, a medical informatics technology company. Previously, she served on the Board of Directors of Cytyc Corporation (NASDAQ: CYTYC) a device and diagnostics company. She was also on the Board of Boehringer Ingelheim Corporation, the world's largest privately owned pharmaceutical company. Ms. Persky was a director of Watermark, Inc. a private publisher and broker of children's literature and on the board of advisors of Text IQ, a technology company that harnesses thepower of artificial intelligence to prevent legal, compliance and reputational disasters. In addition to her corporate activities, Ms. Persky is on the Board of several not-for-profit organizations such as the Leukemia & Lymphoma Society, Primary Stages (Off-Broadway Theater Company) and World Neighbors Inc. Ms. Persky is a frequent speaker on a variety of subjects including leadership principles, career development, board service, mentoring, diversity, and crisis management. She is a graduate of Washington University, School of Law and Northwestern University. Throughout her career, Ms. Persky has focused on improving diversity and inclusion in the legal profession. She has been awarded for her contributions by elite organizations such as the Lawyer's Collaborative for Diversity and the Connecticut Appleseed Foundation. She was recognized as one of the ten most innovative in-house counsel for her strategy and efforts to increase the opportunities and visibility of women in high profile litigation. Many rumors abound about how difficult it is for lawyers to get on corporate boards...too risk averse...no P&L experience...companies already have their own general counsel. What these nay-sayers overlook, however, are the skills and competencies that lawyers, particularly general counsel, bring to boards of directors. Just like sitting CEOs and CFOs are sought for board service, so are general counsel. Join Marla Persky, a former general counsel, as she discusses her pathway to board service. Marla is president and CEO of WOMN LLC and sits on several boards of directors. Somehow she managed to overcome the burden of being a lawyer and found her way to board service.

In this episode of the HR Leaders podcast, I'm joined by my guest Sven Skillrud, Vice President, Total Rewards at Baxter International Inc.Thanks to 365Talents for supporting the show!Download their free E-Book to learn how data can help your organisation effectively address three strategic HR Challenges: https://bit.ly/3keychallengesEpisode highlights00:00 Intro00:27 On the return to the workplace08:04 How a lawyer became VP of Total Rewards15:18 How Total Rewards has been impacted by the pandemic24:54 How Sven launched Headspace26:09 Justifying the investment29:49 How Sven adjusted his employee value proposition34:09 How Baxter's products work37:43 On the future of the rewards spaceIf you enjoyed the podcast be sure to subscribe for more content like this and visit our website to access resources mentioned: www.hrdleaders.com/podcastSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

S&P500 and Nasdaq booked fresh record closing highs as attention turns to tonight's AEST August jobs data - Dow up +131-points or +0.37% . The broader S&P500 added +0.28% to 4,536.95, touching a record intraday high of 4,545.85 earlier in the session. Energy (up +2.53%) led eight of the elven primary sectors higher, with Health Care (+1.08%) and Industrials (+1.02%) both rising over >1%. The global shortage of computer chips continues, forcing automakers to temporarily close factories. General Motors Co (down -0.33%) announced that it would pause production at eight North American plants during the next two weeks, including two that make the company's top-selling Chevrolet Silverado pickup. Ford Motor Co (-0.76%) will stop making pickups at its Kansas City Assembly Plant for the next two weeks. Shifts will be cut at two more truck plants in Dearborn, Michigan, and Louisville, Kentucky. The Nasdaq edged +0.14% higher to 15,331.18, also setting an intraday all-time high (15,380.07). Apple Inc climbed +0.75% to a record closing high of US$153.65 after the most valuable U.S. company by market capitalisation announced concessions for some large developers on its App Store regarding commissions. Apple said late Wednesday (1 September) it will allow developers of so-called “reader” apps, which offer content on a subscription basis like Netflix Inc (+1.11% to US$588.55 and extending their best-ever two-week stretch of gains into record territory) and Spotify Technology SA (+6.57%), to give customers the option of sidestepping its in-app purchase commissions by making direct purchases from the respective companies. Separately, CNBC reported that Apple was preparing mass production of the Apple Car by 2024. The small capitalisation Russell 2000 up +0.74%. In merger and acquisition (M&A) news, Baxter International Inc +4.8% higher after it said it has entered an agreement to acquire fellow medical technology company Hill-Rom Holdings Inc. for US$156 per share, in a deal with an enterprise value of ~US$12.4B.”

S&P500 and Nasdaq booked fresh record closing highs as attention turns to tonight's AEST August jobs data - Dow up +131-points or +0.37% . The broader S&P500 added +0.28% to 4,536.95, touching a record intraday high of 4,545.85 earlier in the session. Energy (up +2.53%) led eight of the elven primary sectors higher, with Health Care (+1.08%) and Industrials (+1.02%) both rising over >1%. The global shortage of computer chips continues, forcing automakers to temporarily close factories. General Motors Co (down -0.33%) announced that it would pause production at eight North American plants during the next two weeks, including two that make the company's top-selling Chevrolet Silverado pickup. Ford Motor Co (-0.76%) will stop making pickups at its Kansas City Assembly Plant for the next two weeks. Shifts will be cut at two more truck plants in Dearborn, Michigan, and Louisville, Kentucky. The Nasdaq edged +0.14% higher to 15,331.18, also setting an intraday all-time high (15,380.07). Apple Inc climbed +0.75% to a record closing high of US$153.65 after the most valuable U.S. company by market capitalisation announced concessions for some large developers on its App Store regarding commissions. Apple said late Wednesday (1 September) it will allow developers of so-called “reader” apps, which offer content on a subscription basis like Netflix Inc (+1.11% to US$588.55 and extending their best-ever two-week stretch of gains into record territory) and Spotify Technology SA (+6.57%), to give customers the option of sidestepping its in-app purchase commissions by making direct purchases from the respective companies. Separately, CNBC reported that Apple was preparing mass production of the Apple Car by 2024. The small capitalisation Russell 2000 up +0.74%. In merger and acquisition (M&A) news, Baxter International Inc +4.8% higher after it said it has entered an agreement to acquire fellow medical technology company Hill-Rom Holdings Inc. for US$156 per share, in a deal with an enterprise value of ~US$12.4B.”

Join David Nour on this episode of the Curve Benders podcast as he hosts Harry Kraemer, Jr., an executive partner with Madison Dearborn Partners, a private equity firm based in Chicago, Illinois, and a Clinical Professor of Leadership at Northwestern University's Kellogg School of Management, where he was named the 2008 Kellogg School Professor of the Year. Harry is the author of three bestselling leadership books: From Values to Action: The Four Principles of Values-Based Leadership, Becoming The Best: Build a World-Class Organization Through Values-Based Leadership. and Your 168: Finding Purpose and Satisfaction in a Values-Based Life. He is the former chairman and chief executive officer of Baxter International Inc., a $12 billion global healthcare company. He became Baxter's chief executive officer in January 1999 and assumed the additional responsibility of chairman of Baxter's board of directors in January 2000. Harry joined Baxter in 1982 as director of corporate development. His twenty-three-year career at Baxter included senior positions in both domestic and international operations. In 1993, he was named senior vice president and chief financial officer, responsible for financial operations, business development, global communications, and European operations. Over the next several years, he assumed additional responsibility for Baxter's Renal and Medication Delivery businesses. He was elected to Baxter's board of directors in 1995 and was named president of Baxter International Inc. in 1997. Before joining Baxter, Mr. Kraemer worked for Bank of America in corporate banking and for Northwest Industries in planning and business development. Mr. Kraemer is active in business, education, and civic affairs. He serves on the board of directors of Leidos Corporation, Dentsply Sirona, Option Care Health, Performance Health, and Alcami, and on the board of trustees of Northwestern University, The Conference Board, NorthShore University Healthsystem and the Archdiocese of Chicago Finance Committee and School Board. He is a member of the Dean's Global Advisory Board of Northwestern University's Kellogg School of Management. He is a member of the Council of CEOs, the Commercial Club of Chicago, the Economics Club of Chicago. He is a past member of the Business Roundtable, the Business Council, and the Healthcare Leadership Council. Mr. Kraemer graduated summa cum laude from Lawrence University of Wisconsin in 1977 with a bachelor's degree in mathematics and economics. He received an MBA degree in finance and accounting from Northwestern University's Kellogg School of Management in 1979 and is a certified public accountant. For his outstanding leadership and service, he received the 1996 Schaffner Award from the Kellogg School of Management. Harry enjoys jogging, tennis, skiing, and reading, especially world civilization. Harry, his wife Julie, and their five children live in Wilmette, Illinois. More info on Harry at www.harrykraemer.org. #CurveBendersBook --- Send in a voice message: https://anchor.fm/david-nour/message

Nektar.ai, a B2B productivity startup, has raised an additional $6 million seed funding round led by B Capital Group, 3One4 Capital, and Nexus Venture Partners. Several well-known Go To Market players in the US-Asia cross-border SaaS ecosystem took part in the round.McAfee Enterprise has announced the launch of MVISION Private Access, an integrated strategy for granular ‘Zero Trust' access and extending data and threat security capabilities to private apps hosted across hybrid IT environments. Baxter International Inc., a global medical products firm, is partnering with Amazon Web Services (AWS). As part of a company-wide push to increase cloud usage, Baxter has extended its multi-year strategic partnership with Amazon Web Services.Bridgestone Americas enters a definitive agreement to purchase Azuga Holdings for $391M from shareholders to strengthen its Silicon Valley presence and accelerate its progress towards delivering sustainable tire-centric and mobility solutions. Salesforce announced a definitive acquisition agreement with Servicetrace (financials undisclosed) to integrate it with a previously acquired company, MuleSoft. The transaction would close this October and the new Robotics Process Automation (RPA) capabilities of Servicetrace would enhance Salesforce's Einstein Automate solution and enable end-to-end workflow automation.Nozomi Networks has announced a $100M in Series D and a pre-IPO funding round led by Triangle Peak Partners. It states that this has been a year of record growth, topping a 110 percent increase in annual recurring revenue and a two-fold increase in customer base.

Jess interviews Lance Scoular, an international trade guru about the risks associated with the importing, exporting and global trading business; and the associated rules, processes, players, documents and costs, so we can learn how to successfully sell our products globally. Show Notes: In this episode, I interview Lance Scoular, an international trade guru who coaches businesses in importing, exporting, and global trading to better navigate the minefield of international trade and transport safely. Lance has been involved in international trade and transport since 1968 in import/export operations for 2 Multinational Companies (3M Australia and Baxter International Inc.) and freight forwarding. He has also been a licensed customs broker, Austrade export adviser, and tutor at a number of universities and community colleges. He's currently an online coach and educator. Lance has an ability to share his extensive knowledge, experience and insights in a clear, simple, and understandable style that will propel you forward toward your success in importing, exporting, international trade, and transport. He comes on to talk about the risks associated with the importing, exporting or global trading business that you have to avoid to succeed. He will also help us better understand the rules, processes, players, documents and costs, and tell us how to mitigate those risks. This is one super resourceful episode that you won't wanna miss, so stayed tuned for more. This Cast Covers: ● How Lance became the guru that he is in import, export, and global trade (02:03) ● Discovering the benefits of social media for small business and pivoting into social media training and consulting (05:01) ● Getting direct coaching from Lance on import and export (06:01) ● The current state of international trade and why it could be the best time to get into it if you have the right product (07:08) ● The steps you can take to get into global trade if you have a great product to offer (11:08) ● Sourcing for manufacturers in different countries that can supply you with the product you wanna deal in (18:20) ● Using “Fulfilled By Amazon” to much more easily and cost effectively import products and sell them on Amazon (19:46) Additional Resources: ● Lance on LinkedIn ● Lance on Twitter Jess Tiffany is an author, speaker, strategist, and marketing consultant. He is a #1 International Best Selling Author (Growth Hacking: Strategically Grow Your Business Connections from Zero to 10K in 365 Days), Marketing Strategist, C.E.O. of the Marketing and Networking University and MNU Digital (Minneapolis Digital Marketing Agency). Founder of the new social media platform Jezster. Making Social Media Fun Again. Please watch out for the new Rev It Up Mastermind! --- Support this podcast: https://anchor.fm/jess-tiffany/support

Are you living your core personal values? If you look carefully at how you're spending your time, how aligned is it with your core values? It's a great time to step back, take stock, and make some changes that can make a big difference in the year(s) ahead. Our guest Harry Kraemer, author of Your 168: Finding Purpose and Satisfaction in a Values-Based Life, highlights how self-reflection can help create greater alignment and flexibility. A Values Based Life Our conversation covers a lot of ground: Why 168 is his favorite number. After the books he's written on leadership, what inspired him to write Your 168. What a life based on values looks like versus one that’s less so. Why self-reflection is so important – and how it's part of his day. How planning and spontaneity can co-exist. What the transition was like for him when he retired  – and what led him to teach in the MBA program at Kellogg. What a friend and colleague learned from a wake-up call. The role habits play in a values-based life. Why genuine humility and making a difference are key parts of a values-based life. His involvement in the One Acre Fund. The best way to start if you want to make the most of your 168 starting in 2021. __________________________ Bio Harry M. Jansen Kraemer, Jr. is an executive partner with Madison Dearborn Partners, a private equity firm based in Chicago, Illinois and a Clinical Professor of Leadership at Northwestern University's Kellogg School of Management. He was named the 2008 Kellogg School Professor of the Year. Harry is the author of two bestselling leadership books: From Values to Action: The Four Principles of Values-Based Leadership and Becoming The Best: Build a World-Class Organization Through Values-Based Leadership. He is the former chairman and chief executive officer of Baxter International Inc., a $12 billion global healthcare company. He became Baxter's chief executive officer in January 1999, and assumed the additional responsibility of chairman of Baxter's board of directors in January 2000. Mr. Kraemer joined Baxter in 1982 as director of corporate development. His twenty-three year career at Baxter included senior positions in both domestic and international operations. In 1993, he was named senior vice president and chief financial officer, responsible for financial operations, business development, global communications, and European operations. Over the next several years, he assumed additional responsibility for Baxter's Renal and Medication Delivery businesses. He was elected to Baxter's board of directors in 1995, and was named president of Baxter International Inc. in 1997. Before joining Baxter, Mr. Kraemer worked for Bank of America in corporate banking and for Northwest Industries in planning and business development. Mr. Kraemer is active in business, education and civic affairs. He serves on the board of directors of Leidos Corporation, Dentsply Sirona, Option Care Health, Performance Health and Alcami, and on the board of trustees of Northwestern University, The Conference Board, NorthShore University Healthsystem and the Archdiocese of Chicago Finance Committee and School Board. He is a member of the Dean's Global Advisory Board of Northwestern University's Kellogg School of Management. He is a member of the Council of CEOs, the Commercial Club of Chicago, the Economics Club of Chicago. He is a past member of the Business Roundtable, the Business Council, and the Healthcare Leadership Council. Mr. Kraemer graduated summa cum laude from Lawrence University of Wisconsin in 1977 with a bachelor's degree in mathematics and economics. He received an MBA degree in finance and accounting from Northwestern University's Kellogg School of Management in 1979 and is a certified public accountant. For his outstanding leadership and service, he received the 1996 Schaffner Award from the Kellogg School of Management. Harry enjoys jogging, tennis,

In this episode, our podcast host Dr. Emily Church looks at how technology is innovating modern medicine at an exponential rate to be smarter and proactive. In a special recording from Visioneering, XPRIZE founder Peter H. Diamandis is joined by two of the world’s greatest entrepreneurs: iBOT & Segway inventor engineer Dean Kamen, and science innovator and founder of United Therapeutics, Martine Rothblatt. They discuss the future of health and medicine where biology IS technology. Drawing from their own inspirational experience, including printing new organs, and eradicating diabetes and Alzheimers, Peter, Dean and Martine discuss the positive impact that innovation is having on human health and longevity. Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released on January 28, 2020. He earned degrees in molecular genetics and aerospace engineering from the MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.”Dr. Martine Rothblatt founded Lung Biotechnology, as well as its parent company, United Therapeutics, in order to develop therapies for orphan diseases such as PAH. She earned her PhD in medical ethics from the Royal London School of Medicine and Dentistry, Queen Mary College, University of London and also obtained JD and MBA degrees from the University of California at Los Angeles. Prior to entering the life sciences field, Dr. Rothblatt was active in satellite communications, founding Sirius XM Satellite Radio and serving as its Chairman and CEO. She has also published many books, including Your Life or Mine: How Geoethics Can Resolve the Conflict Between Public and Private Interests in Xenotransplantation.Dean Kamen, Founder of FIRST and President of DEKA Research & Development CorporationDean Kamen is an inventor, an entrepreneur, and a tireless advocate for science and technology. His roles as inventor and advocate are intertwined—his own passion for technology and its practical uses has driven his personal determination to spread the word about technology's virtues and by so doing to change the culture of the United States.As an inventor, he holds more than 440 U.S. and foreign patents, many of them for innovative medical devices that have expanded the frontiers of health care worldwide. While still a college undergraduate, he invented the first wearable infusion pump, which rapidly gained acceptance from such diverse medical specialties as oncology, neonatology, and endocrinology. In 1976, he founded his first medical device company, AutoSyringe, Inc., to manufacture and market the pumps. Then, working with leading diabetes researchers, Dean pioneered the design and adoption of the first portable insulin pump. It was quickly demonstrated that using a pump could much more effectively control patients’ blood glucose levels. . At age 30, he sold AutoSyringe to Baxter Healthcare Corporation. Following the sale of AutoSyringe, Inc., he founded DEKA Research & Development Corporation to develop internally generated inventions as well as to provide research and development for major corporate clients. Kamen led DEKA's development of the HomeChoiceTM peritoneal dialysis system for Baxter International Inc. The HomeChoiceTM system allows patients to be dialyzed in the privacy and comfort of their home and quickly became the worldwide market leader. Kamen also led the development of technology to improve slide preparation for the CYTYC (now Hologic Inc.) ThinPrep® Pap Test. Kamen-led DEKA teams have also developed critical components of the UVARTM XTSTM System, an extracorporeal photophereisis device marketed by Therakos, a unit of Johnson & Johnson, for treatment of T-Cell lymphoma. An advanced prosthetic arm in development for DARPA should advance the quality of life for returning injured soldiers. Other notable developments include the HydroflexTM surgical irrigation pump for C.R. Bard, the CrownTM stent, an improvement to the original Palmaz-Schatz stent, for Johnson & Johnson, the iBOTTM mobility device, and the Segway® Human Transporter.Kamen has received many awards for his efforts. Notably, Kamen was awarded the National Medal of Technology in 2000. Presented by President Clinton, this award was in recognition for inventions that have advanced medical care worldwide, and for innovative and imaginative leadership in awakening America to the excitement of science and technology. Kamen was elected a member of the National Academy of Engineering in 1997. He was awarded the Lemelson-MIT Prize in 2002, and was inducted into the National Inventors Hall of Fame in May 2005. He is a Fellow of the American Institute for Medical & Biological Engineering, as well as many other national and international engineering organizations.In 2010, Dean hosted the Planet Green television series Dean of Invention.In addition to DEKA, one of Dean's proudest accomplishments is founding FIRST® (For Inspiration and Recognition of Science and Technology), an organization dedicated to motivating the next generation to understand, use and enjoy science and technology. Founded in 1989, this year FIRST® will serve more than 1,000,000 young people, ages 6 to 18, in more than 86 countries around the globe. Last year, high-school-aged participants were eligible to apply for more than $50 million in scholarships from over 200 leading colleges, universities, and corporations.Links: https://www.firstinspires.org/robotics/frchttps://www.unither.com/ See acast.com/privacy for privacy and opt-out information.

with Jeanne Mason, CVP Human Resources, Baxter International Inc.  Q&A Podcast

In today's unsteady world, high values are hardly overly evident. As a term, "values-based" maybe be misunderstood or abused. To aspire to and achieve values-based entrepreneurship, it begins with you. Join ENCLAVE and Harry Kraemer, an executive partner with Madison Dearborn Partners and former Chairman and CEO of Baxter International Inc, as we discuss values in today's society.  ENCLAVE For Entrepreneurs  Harry Kraemer

Harry Kraemer is the former Chairman and CEO of Baxter International Inc. -- a multi-billion-dollar global healthcare company -- and author of two books on values-based leadership: From Values to Action: The Four Principles of Values-Based Leadership and Becoming The Best: Build a World-Class Organization Through Values-Based Leadership. Harry is a clinical professor of management and strategy at Northwestern University’s Kellogg School of Management. He is an executive partner with Madison Dearborn Partners, one of the largest private equity firms in the United States, where he consults with CEOs and other senior executives of companies in MDP’s extensive portfolio. Stew and Harry discuss the importance of knowing yourself and your values in order to motivate, inspire, and lead others. They discuss strategies for how to develop effective values-based leadership through self-reflection, listening, and being open to others’ perspectives. Leaders must challenge themselves to take an honest look at their personal values and determine how to incorporate those into their daily activities. By developing this self-awareness, leaders can instill a more meaningful sense of purpose in their work and in the rest of their lives. The second half includes some interesting questions from callers so be sure to listen for Harry’s responses. See acast.com/privacy for privacy and opt-out information.

Mike has developed a unique perspective from 20+ years of working alongside a star studded list of world-renowned thought leaders, including: Dr. John Kotter, Dr. Stephen Covey, Tom Peters, Jim Kouzes, Hyrum Smith, Steve Farber and Chris McChesney. Mike served in senior leadership and consulting roles with Kotter International, FranklinCovey, and Tom Peters Company. In addition to being a leading authority on Unleashing Personal and Organizational Accountability, clients rely upon Mike’s solutions to; Accelerate Change, Shape Their Optimal Culture, Flawlessly Execute Key Strategies, Ignite Leadership Capacity at all Levels, and Amplify Employee Engagement. Mike works with organizations around the globe and in virtually every arena, from the tech sector to financial services, manufacturing, health care, hospitality, entertainment, retail, and the US Government. Clients include: Intel, Capital One, Apple, BNY Mellon, Pfizer, The United States Navy, Fidelity Investments, Johnson & Johnson, Symantec, Cigna Corporation, PharMerica, Oracle, Astra Zeneca, Baxter International Inc., Shell Oil, Cargill, American Airlines, DuPont USA, and NASA.  Mike consults with senior teams, facilitates custom workshops, delivers keynote speeches and provides coaching and consulting on all of these subject areas. He uses his unique insights, passion, experience, and humor to positively affect individuals, teams and organizations around the world. He is experienced with executive leadership teams and groups at all organizational levels. His style is engaging, upbeat, entertaining, thought-provoking, compelling, and most importantly educational, relevant and impactful. Individuals, teams and organizations yield immediate results by applying what they learn. His personal mission is to help individuals, teams and organizations accelerate their ability to achieve more than they ever believed possible. Clients describe him as inspiring, motivating and a ball of energy with an unequalled focus and passion for helping them achieve their desired results.   Contact Mike:    mike.evans@questmarkcompany.com   PEAK PERFORMANCE NATION A community dedicated to raising your game to the next level by learning how to Execute at the highest level and eliminating the obstacles that keep you from being the leader you were born to be. Join group here:  https://www.facebook.com/groups/PeakPerformanceNation/   SPONSORS & FREE OFFERS Audible - Free Audio Book & 30 Day Trial  Blue Apron -  $30 Off Your First Order   Acuity Scheduling - Stop Wasting Time Setting Up Meetings Peak Accountability - http://www.thorconklin.com/accountability/   Thank you once again for listening   Please follow us on:   Facebook: Thor Conklin    Twitter: @ThorConklin Website: http://www.thorconklin.com   ThorConklin.com Thor Conklin Media Peak Performers Podcast Peak Performance Nation   #1 Podcast on how to get things done.  Learn from Peak Performers in all areas of life and Business.  Do you know what to do but can't figure out why you are not executing what you already know?   If so, this Podcast will give you the tools, strategies and psychology to not only break through the choke point but to truly become a Peak Performer.   Thor will be sharing his tools and strategies as well as interviewing inspiring Peak Performers that are Entrepreneur's, Professional Athletes, Business leaders, Military, Technology guru's, Health and Fitness masters, Relationships Experts as well as Music & Entertainment superstars.   Mission and Purpose - To engage, educate, entertain and inspire listeners to excel in any area of life through mastering the science of execution and Peak Performance.  You will learn the necessary road map, strategies, tools and psychology to win this game.      

Mike has developed a unique perspective from 20+ years of working alongside a star studded list of world-renowned thought leaders, including: Dr. John Kotter, Dr. Stephen Covey, Tom Peters, Jim Kouzes, Hyrum Smith, Steve Farber and Chris McChesney. Mike served in senior leadership and consulting roles with Kotter International, FranklinCovey, and Tom Peters Company. In addition to being a leading authority on Unleashing Personal and Organizational Accountability, clients rely upon Mike’s solutions to; Accelerate Change, Shape Their Optimal Culture, Flawlessly Execute Key Strategies, Ignite Leadership Capacity at all Levels, and Amplify Employee Engagement. Mike works with organizations around the globe and in virtually every arena, from the tech sector to financial services, manufacturing, health care, hospitality, entertainment, retail, and the US Government. Clients include: Intel, Capital One, Apple, BNY Mellon, Pfizer, The United States Navy, Fidelity Investments, Johnson & Johnson, Symantec, Cigna Corporation, PharMerica, Oracle, Astra Zeneca, Baxter International Inc., Shell Oil, Cargill, American Airlines, DuPont USA, and NASA.  Mike consults with senior teams, facilitates custom workshops, delivers keynote speeches and provides coaching and consulting on all of these subject areas. He uses his unique insights, passion, experience, and humor to positively affect individuals, teams and organizations around the world. He is experienced with executive leadership teams and groups at all organizational levels. His style is engaging, upbeat, entertaining, thought-provoking, compelling, and most importantly educational, relevant and impactful. Individuals, teams and organizations yield immediate results by applying what they learn. His personal mission is to help individuals, teams and organizations accelerate their ability to achieve more than they ever believed possible. Clients describe him as inspiring, motivating and a ball of energy with an unequalled focus and passion for helping them achieve their desired results.   Contact Mike:    mike.evans@questmarkcompany.com   PEAK PERFORMANCE NATION A community dedicated to raising your game to the next level by learning how to Execute at the highest level and eliminating the obstacles that keep you from being the leader you were born to be. Join group here:  https://www.facebook.com/groups/PeakPerformanceNation/   SPONSORS & FREE OFFERS Audible - Free Audio Book & 30 Day Trial  Blue Apron -  $30 Off Your First Order   Acuity Scheduling - Stop Wasting Time Setting Up Meetings Peak Accountability - http://www.thorconklin.com/accountability/   Thank you once again for listening   Please follow us on:   Facebook: Thor Conklin    Twitter: @ThorConklin Website: http://www.thorconklin.com   ThorConklin.com Thor Conklin Media Peak Performers Podcast Peak Performance Nation   #1 Podcast on how to get things done.  Learn from Peak Performers in all areas of life and Business.  Do you know what to do but can't figure out why you are not executing what you already know?   If so, this Podcast will give you the tools, strategies and psychology to not only break through the choke point but to truly become a Peak Performer.   Thor will be sharing his tools and strategies as well as interviewing inspiring Peak Performers that are Entrepreneur's, Professional Athletes, Business leaders, Military, Technology guru's, Health and Fitness masters, Relationships Experts as well as Music & Entertainment superstars.   Mission and Purpose - To engage, educate, entertain and inspire listeners to excel in any area of life through mastering the science of execution and Peak Performance.  You will learn the necessary road map, strategies, tools and psychology to win this game.      

Mike has developed a unique perspective from 20+ years of working alongside a star studded list of world-renowned thought leaders, including: Dr. John Kotter, Dr. Stephen Covey, Tom Peters, Jim Kouzes, Hyrum Smith, Steve Farber and Chris McChesney. Mike served in senior leadership and consulting roles with Kotter International, FranklinCovey, and Tom Peters Company. In addition to being a leading authority on Unleashing Personal and Organizational Accountability, clients rely upon Mike’s solutions to; Accelerate Change, Shape Their Optimal Culture, Flawlessly Execute Key Strategies, Ignite Leadership Capacity at all Levels, and Amplify Employee Engagement. Mike works with organizations around the globe and in virtually every arena, from the tech sector to financial services, manufacturing, health care, hospitality, entertainment, retail, and the US Government. Clients include: Intel, Capital One, Apple, BNY Mellon, Pfizer, The United States Navy, Fidelity Investments, Johnson & Johnson, Symantec, Cigna Corporation, PharMerica, Oracle, Astra Zeneca, Baxter International Inc., Shell Oil, Cargill, American Airlines, DuPont USA, and NASA.  Mike consults with senior teams, facilitates custom workshops, delivers keynote speeches and provides coaching and consulting on all of these subject areas. He uses his unique insights, passion, experience, and humor to positively affect individuals, teams and organizations around the world. He is experienced with executive leadership teams and groups at all organizational levels. His style is engaging, upbeat, entertaining, thought-provoking, compelling, and most importantly educational, relevant and impactful. Individuals, teams and organizations yield immediate results by applying what they learn. His personal mission is to help individuals, teams and organizations accelerate their ability to achieve more than they ever believed possible. Clients describe him as inspiring, motivating and a ball of energy with an unequalled focus and passion for helping them achieve their desired results.   Contact Mike:   mike.evans@questmarkcompany.com   PEAK PERFORMANCE NATION A community dedicated to raising your game to the next level by learning how to Execute at the highest level and eliminating the obstacles that keep you from being the leader you were born to be. Join group here:  https://www.facebook.com/groups/PeakPerformanceNation/   SPONSORS & FREE OFFERS Audible - Free Audio Book & 30 Day Trial  Blue Apron -  $30 Off Your First Order   Acuity Scheduling - Stop Wasting Time Setting Up Meetings Peak Accountability - http://www.thorconklin.com/accountability/   Thank you once again for listening   Please follow us on:   Facebook: Thor Conklin    Twitter: @ThorConklin Website: http://www.thorconklin.com   ThorConklin.com Thor Conklin Media Peak Performers Podcast Peak Performance Nation   #1 Podcast on how to get things done.  Learn from Peak Performers in all areas of life and Business.  Do you know what to do but can't figure out why you are not executing what you already know?   If so, this Podcast will give you the tools, strategies and psychology to not only break through the choke point but to truly become a Peak Performer.   Thor will be sharing his tools and strategies as well as interviewing inspiring Peak Performers that are Entrepreneur's, Professional Athletes, Business leaders, Military, Technology guru's, Health and Fitness masters, Relationships Experts as well as Music & Entertainment superstars.   Mission and Purpose - To engage, educate, entertain and inspire listeners to excel in any area of life through mastering the science of execution and Peak Performance.  You will learn the necessary road map, strategies, tools and psychology to win this game.      

1) Clinical and serological characterization of the antibodies to GABAA receptor a1 and y2 subunits and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Lara Marcuse interviews Dr. Angela Vincent about her paper on the clinical and serological characterization of the antibodies to GABAA receptor a1 and y2 subunits. Dr. James Addington is reading our e-Pearl of the week about navigating painful neuropathies. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Steve Zeiler about the topic of stroke in the setting of CNS vasculitis. The participants had nothing to disclose except Drs. Vincent, Addington, Johansen and Zeiler.Dr. Vincent serves on the advisory editorial board Journal of Neurology; holds patent with Oxford University for LGI1/CASPR2 antibodies, licensed to Euroimmun AG, and for GABAAR antibodies, in negotiation with Euroimmun AG; was a consultant with Athena Diagnostics; occasional small honoraria, travel and speaker honoraria from Baxter International Inc. and Biogen Idec; receives royalties from Athena Diagnostics (MuSK assays), from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010); and receives research support from the NIH.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Zeiler receives research support from Johns Hopkins Neurology and NIH; has provided expert legal testimony in 2013 and 2014.

1) Guillain-Barre syndrome being associated with hepatitis E virus infection and 2) Topic of the month: Review of new oral anticoagulants for stroke. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bart Jacobs about his paper on Guillain-Barre syndrome being associated with hepatitis E virus infection. Dr. James Addington is reading our e-Pearl of the week about myelin-oligodendrocyte glycoprotein antibody. In the next part of the podcast Dr. Mark McAllister interviews Dr. Seemant Chaturvedi about a brief review of new oral anticoagulant (Rivaroxaban), reference clinical trial, indication and dosing. The participants had nothing to disclose except Drs. Burns, Jacobs, Addington and Chaturvedi.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals.Dr. Jacobs serves as an editorial board member for Journal of the Peripheral Nerve System; received funding for travel from Baxter International Inc. for a scientific meeting; received research support from the Netherlands Organization for Health Research and Development, Erasmus MC, Prinses Beatrix Spierfonds, GBS-CIDP Foundation International.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Chaturvedi serves as an editorial board member for Neurology®, Stroke; serves as contributing editor NEJM Journal Watch Neurology; serves as executive committee member for ACT I study; is a consultant for Genetech, Inc., Boehringer Ingelheim, Abbott Vascular, Thorhill research, WL Gore, Bristol-Myers Squibb; receives research support from Daichi Sankyo, AstraZeneca, Pfizer Inc, NIH; received compensation for expert witness testimony.

1) Risk factors for dementia with Lewy bodies and 2) Topic of the month: Frontotemporal degeneration. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Geldmacher interviews Dr. Brendon Boot about his paper on risk factors for dementia with Lewy bodies. Dr. Adam Numis is reading our e-Pearl of the week about reversible cerebral vasoconstriction syndrome. In the next part of the podcast Dr. Brandy Matthews focuses her interview with Dr. Bill Seeley about therapeutics and future directions in frontotemporal degeneration. The participants had nothing to disclose except Drs. Geldmacher, Numis, Matthews and Seeley.Dr. Geldmacher serves as an editorial board member of Brain Injury; serves on a Data Safety Committee for GlaxoSmithKline; received research support from Baxter International Inc., Elan Corporation, Eisai Inc.; received honoraria for consulting from Abbvie, Janssen Alzheimer Immunotherapy, and Baxter International Inc. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Matthews receives research support from the NIH.Dr. Seeley serves as an editorial board member for Annuals of Neurology; served on the scientific advisory board for Bristol-Myers Squibb; is a consultant for Summer Street Research Partners; received speaker honorarium from Novartis Korea; received research support from the John Douglas French Alzheimer's Disease Foundation, Consortium for Frontotemporal Dementia Research; Tau Consortium, James S. McDonnell Foundation, Alzheimer's Disease Drug Foundation, Association for Frontotemporal Dementia and National Institute on Aging.

1) MuSK myasthenia and 2) Topic of the month: Ethics Issues. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Isabel Illa about her paper on the effect of rituximab in MuSK myasthenia. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about Möbius syndrome. In the next part of the podcast Dr. Nandini Muralidharan interviews Dr. Michael Schneck about conflicting values in withdrawal of support. Over the next two weeks, we will have additional interviews regarding ethic issues. The participants had nothing to disclose except Drs. Burns, Illa, Clardy and Schneck.Dr. Illa has received funding for travel from Genzyme Corporation; serves on the editorial board of Neurologia; is listed as author on patent(s) re: Dysferlin detection in monocytes licensed to Athena Diagnostics, Inc.; and receives research support from Grifols, FIS (Fondo de Investigaciones Sanitarias), ISCIII, Ministry of Health (Spain), and Fundacion Gemio. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Schneck serves on data safety monitoring boards for Talecris Biotherapeutics, Chelsea Therapeutics, and Baxter International Inc.; serves on the editorial advisory boards for the Journal of Stroke and Cerebrovascular Disease and Frontiers in Neurocritical Care and Neurohospitalist Care; receives publishing royalties from Continuum; serves on the speakers' bureaus for Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Boehringer Ingelheim, and Pfizer Inc; and receives research support from NMT Medical, Schering-Plough Corp., and the NIH.

1) Guillain-Barré syndrome and 2) Topic of the month: Sports neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Bart Jacobs about his paper on Guillain-Barré syndrome. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about early handedness a sign of presumed perinatal stroke. In the next part of the podcast Dr. Howard Goodkin interviews Dr. Jeff Kutcher about concussion diagnosis. The LOTWs for the next two weeks of March will be post-concussion syndrome and peripheral nerve injury. The participants had nothing to disclose except Drs. Burns, Jacobs, Fugate and Goodkin.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Jacobs has received funding for travel from Baxter International Inc.; and has received research support from the Netherlands Organization for Health Research and Development, the Prinses Beatrix Fonds, and from GBS-CIDP Foundation International. Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Goodkin serves on the scientific board for Tuberous Sclerosis Alliance and CURE; serves on the editorial board for Neurology and Surgical Neurology International; receives royalties from the publication of the book The choking game and other strangulation activities in children and adolescents; and is funded by NIH grants [R01 NS067439 PI and R01 NS48413 PI].

1) Nonfluent primary progressive aphasia and 2) MuSK antibodies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Jonathan Rohrer about his paper on nonfluent primary progressive aphasia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Stransky sign. In the next part of the podcast Dr. Beau Bruce interviews Dr. Donald Sanders about MuSK antibodies for our Lesson of the Week. The participants had nothing to disclose except Drs. Rohrer, Mateen, Overman, Bruce and Sanders. Dr. Mateen has received grant funding from the AAN/AANF 2010 Practice Research Fellowship. Dr. Rohrer has received research support from the Wellcome Trust (Clinical Research Fellowship) and Brain (Exit Scholarship).Dr. Overman serves as Deputy Editor on the Neurology(R) Resident and Fellow Section editorial team and the Neurology(R) Podcast Committee.Dr. Bruce has received grant funding from the AAN/AANF Practice Research Fellowship and is funded by NIH grants UL1-RR025008 and KL2-RR025009.Dr. Sanders is a consultant for Accordant Health Services, Inc, Bayhill Therapeutics, Inc, Jacobus Pharmaceutical Co., Inc, BioMarin, Inc, Baxter International Inc., CytoKinetics, GlaxoSmithKline, and GTC Biotherapeutics, Inc, receives royalties from the publication of the book Single Fiber EMG and serves on the speakers' bureau of Athena Diagnostics and Talecris Biotherapeutics.

1) Acute progressive neurologic decline and absence of mass lesion and 2) AAN.com and community features it provides. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Karen Roos interviews Drs. Jason Taub and Jeffrey Olson about their paper on acute progressive neurologic decline. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about unilateral photophobia or phonophobia in cluster headache. In the next part of the podcast Dr. Ted Burns interviews Dr. Daniel Hoch and Jose Merino about AAN.com and the community features it provides for our Lesson of the Week. The participants had nothing to disclose except Drs. Roos, Olson, Overman, Burns, Hoch, and Jose Merino. Dr. Roos serves as Editor-in-Chief of Seminars in Neurology, received royalties for 4 published textbooks, received funding for traveling from the AAN and other universities, and gave expert testimony, but monies received were forwarded to the Department of Neurology, Indiana University School of Medicine.Dr. Olson serves on the Data Safety Monitoring Board for Monteris, Inc., and has funded clinical research for which he is the Emory PI by Wyeth, Myriad Genetics, Inc., and Baxter International Inc.; and receives research support from the NIH (UO1CA137433-01 [Site PI], R01 CA116174 [Co-I], R01 CA121320-01 [Co-I], and R21 CA141836 [PI]).Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Hoch serves as an editorial board member of AAN.com, holds stock options in Merck Serono and Biogen Idec, and gave expert testimony in the trial for the State of Massachusetts, Essex County, 2008-2010.Jose Merino receives a stipend as Associate Editor for AAN.com, serves as an editorial board member of Stroke and receives salary support from NINDS contract with Suburban Hospital.

U.S. officials announced that Heparin has been linked to 149 deaths in people who had allergic reactions after taking the widely prescribed blood thinner medication. The new tally was posted on June 16, 2008 and can be found the FDA’S website. These new statistics expands the toll of people who took the Heparin and suffered allergic reactions. The agency said in April 2008 it knew of 81 people who died after suffering allergic reactions from the drug, made from pig intestines. Baxter International Inc. recalled its version of Heparin in January 2008 after reports of harmful side effects. Baxter has said it believes the blood thinner was intentionally contaminated during the manufacturing process in China. Members of Congress have called for drug makers to pay higher fees to fund inspection of overseas factories that make drug ingredients.

U.S. officials announced that Heparin has been linked to 149 deaths in people who had allergic reactions after taking the widely prescribed blood thinner medication. The new tally was posted on June 16, 2008 and can be found the FDA’S website. These new statistics expands the toll of people who took the Heparin and suffered allergic reactions. The agency said in April 2008 it knew of 81 people who died after suffering allergic reactions from the drug, made from pig intestines. Baxter International Inc. recalled its version of Heparin in January 2008 after reports of harmful side effects. Baxter has said it believes the blood thinner was intentionally contaminated during the manufacturing process in China. Members of Congress have called for drug makers to pay higher fees to fund inspection of overseas factories that make drug ingredients.